Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Aflibercept + Docetaxel||Phase III||Actionable||In a Phase III trial, the combination of Zaltrap (aflibercept) and Taxotere (docetaxel) did not result in improved overall survival compared to Taxotere (docetaxel) with placebo, but did result in an improved overall response rate of 23.3% (94/404) vs. 8.9% (36/406) with Taxotere (docetaxel) plus placebo in non-small cell lung cancer patients that had failed platinum therapy (PMID: 22965962).||22965962|